JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma

  • 0Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, 050017, Hebei, People's Republic of China.
Scientific Reports +

|

September 16, 2024

|

September 16, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A new index combining the DeRitis ratio (AST/ALT) and alkaline phosphatase (ALP), called DALP, effectively predicts the risk of portal vein tumor thrombosis (PVTT) in liver cancer patients. This index aids in tertiary prevention strategies for hepatocellular carcinoma (HCC) with PVTT.

Area Of Science

  • Hepatocellular Carcinoma Research
  • Oncology Biomarkers
  • Liver Cancer Diagnostics

Background

  • Portal vein tumor thrombosis (PVTT) is a frequent complication of hepatocellular carcinoma (HCC), indicating advanced disease and poor prognosis.
  • PVTT signifies deteriorating liver function, increased risk of metastasis, and portal hypertension-related complications.
  • Novel strategies are needed for predicting and managing PVTT in HCC patients.

Purpose Of The Study

  • To evaluate the diagnostic value of a combined index, the DeRitis ratio (AST/ALT) and alkaline phosphatase (ALP) index (DALP), in predicting PVTT risk in HCC patients.
  • To establish the predictive effectiveness and optimal cut-off value of DALP for PVTT occurrence.
  • To assess the association of DALP with prognosis and clinicopathological features in HCC patients with PVTT.

Main Methods

  • Retrospective study of HCC patients from January 2017 to December 2020.
  • Receiver Operating Characteristic (ROC) analysis to determine DALP's predictive effectiveness and optimal cut-off value (1.045, AUC 0.793).
  • Kaplan-Meier analysis for survival probabilities and Logistics regression for risk assessment.

Main Results

  • The DALP index demonstrated significant predictive value for PVTT occurrence in HCC patients (AUC=0.793).
  • DALP classification (scores 0-2) correlated with distinct prognoses, including 1-year overall survival (100% for score 0 vs. 72.4% for score 2).
  • Higher DALP scores were associated with increased PVTT progression risk (OR 5.822), advanced tumor stage, extrahepatic metastasis, ascites, and severe hepatic inflammation.

Conclusions

  • The combined DeRitis ratio and ALP index (DALP) offers a valuable tool for predicting PVTT occurrence in HCC patients.
  • DALP classification aids in risk stratification, prognosis assessment, and potentially guides tertiary prevention strategies.
  • This index contributes to better management of HCC patients at risk for PVTT.

Keywords: